To date, there is a lack of characterization of metabolic markers in migraine studies. Though numerous studies implicate cerebral dysfunction, robust biomarkers are yet to be identified in the migraine brain. It thus follows that identification of specific metabolic changes, potentially influenced by excitatory and inhibitory neurotransmitters, may improve understanding of migraine onset and propagation while opening new avenues for therapy development.
With the goal of evaluating metabolic processes, diffusion-weighed spectroscopy is used to identify longitudinal changes in the in vivo thalamus of an acute rodent of migraine model.
This abstract and the presentation materials are available to members only; a login is required.